ZA952214B - Methods and compositions useful for inhibiting angiogenesis - Google Patents

Methods and compositions useful for inhibiting angiogenesis

Info

Publication number
ZA952214B
ZA952214B ZA952214A ZA952214A ZA952214B ZA 952214 B ZA952214 B ZA 952214B ZA 952214 A ZA952214 A ZA 952214A ZA 952214 A ZA952214 A ZA 952214A ZA 952214 B ZA952214 B ZA 952214B
Authority
ZA
South Africa
Prior art keywords
methods
compositions useful
inhibiting angiogenesis
angiogenesis
inhibiting
Prior art date
Application number
ZA952214A
Other languages
English (en)
Inventor
Peter Brooks
David A Cheresh
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22783992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA952214(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of ZA952214B publication Critical patent/ZA952214B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
ZA952214A 1994-03-18 1995-03-17 Methods and compositions useful for inhibiting angiogenesis ZA952214B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/210,715 US5753230A (en) 1994-03-18 1994-03-18 Methods and compositions useful for inhibition of angiogenesis

Publications (1)

Publication Number Publication Date
ZA952214B true ZA952214B (en) 1996-02-08

Family

ID=22783992

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA952214A ZA952214B (en) 1994-03-18 1995-03-17 Methods and compositions useful for inhibiting angiogenesis

Country Status (25)

Country Link
US (7) US5753230A (ja)
EP (3) EP0754059B2 (ja)
JP (2) JP4268222B2 (ja)
KR (1) KR100327081B1 (ja)
CN (1) CN1161152C (ja)
AT (3) ATE490784T1 (ja)
AU (1) AU709645B2 (ja)
CA (1) CA2184493C (ja)
CZ (1) CZ294650B6 (ja)
DE (2) DE69536128D1 (ja)
DK (3) DK0754059T4 (ja)
ES (3) ES2211901T5 (ja)
FI (1) FI121916B (ja)
HK (1) HK1013960A1 (ja)
HU (1) HU221988B1 (ja)
MX (1) MX9604145A (ja)
NO (1) NO322441B1 (ja)
NZ (3) NZ511293A (ja)
PT (2) PT1468695E (ja)
RU (1) RU2162712C2 (ja)
SI (1) SI0754059T2 (ja)
SK (1) SK284586B6 (ja)
UA (1) UA44729C2 (ja)
WO (1) WO1995025543A1 (ja)
ZA (1) ZA952214B (ja)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6949511B1 (en) 1994-04-26 2005-09-27 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
US6440729B1 (en) * 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
AU726793B2 (en) * 1995-08-14 2000-11-23 Scripps Research Institute, The Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
MX9801716A (es) 1995-08-30 1998-05-31 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
CZ117798A3 (cs) 1995-10-23 1998-08-12 The Children's Medical Center Corporation Antiangiogenní kompozice a způsoby léčby
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
US6589755B1 (en) * 1996-08-15 2003-07-08 Novartis Ag Assay for quantifying arthritic conditions
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
ES2321991T3 (es) * 1996-12-09 2009-06-15 Merck Patent Gmbh Receptor de adhesion alfavbet3 recombinante soluble.
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
WO1998040488A1 (en) * 1997-03-12 1998-09-17 Smithkline Beecham Corporation Anti-alphabeta3 humanized monoclonal antibodies
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US5994388A (en) * 1997-03-18 1999-11-30 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
EP1003429B1 (en) * 1997-03-19 2008-09-24 Lucid, Inc. Cellular surgery utilizing confocal microscopy
AU6954498A (en) * 1997-04-11 1998-11-11 G.D. Searle & Co. Methods for using antagonistic anti-avb3 integrin antibodies
DE69808609T2 (de) * 1997-04-11 2003-06-12 G.D. Searle & Co., Chicago Antagonistische anti-avb3 integrin antikörper
US6596276B1 (en) * 1997-09-30 2003-07-22 Beth Israel Deaconess Medical Center Method for inhibiting tumor angiogenesis in a living subject
US6172256B1 (en) * 1998-03-04 2001-01-09 G.D. Searle & Co. Chiral-β-amino acid compounds and derivatives thereof
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
SK13952000A3 (sk) 1998-03-31 2001-12-03 Dupont Pharmaceuticals Company Farmaceutické zlúčeniny na zobrazovanie porúch angiogenézy
US6524553B2 (en) * 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US7387779B2 (en) * 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
AU2004202605B2 (en) 1998-07-13 2007-10-25 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
RU2167425C2 (ru) * 1998-07-17 2001-05-20 Малышев Игорь Юрьевич Способ определения белков
US6164281A (en) * 1998-07-20 2000-12-26 Zhao; Iris Ginron Method of making and/or treating diseases characterized by neovascularization
JP2002522504A (ja) * 1998-08-13 2002-07-23 ジー・ディー・サール・アンド・カンパニー 多価ａｖｂ３および転移関連レセプター・リガンド
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US7176289B1 (en) 1998-09-11 2007-02-13 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US6235877B1 (en) 1999-08-04 2001-05-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
US20030202977A1 (en) * 1998-11-16 2003-10-30 New York University Treatment of osteoarthritis
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
US6339062B1 (en) * 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) * 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
BR9917079A (pt) 1998-12-18 2001-10-30 Du Pont Pharm Co Compostos antagonistas de receptor devitronectina, kit, composição metalofarmacêuticade diagnóstico ou terapêutica, composição deagente de contraste para ultra-som, composiçãoradiofarmacêutica terapêutica, composiçãofarmacêutica de diagnóstico, método detratamento da artrite reumatóide, do cancêr e darestenose em um paciente, método de formação deimagem da angiogênese terapêutica, do câncer, denovos vasos sanguìneos, da arteriosclerose, darestenose, da isquemia e da lesão por reperfusãodo miocárdio em um paciente
WO2000038715A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
RU2236251C2 (ru) * 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
WO2000059532A1 (en) * 1999-04-01 2000-10-12 Biostratum, Inc. The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
AU4982200A (en) * 1999-05-06 2000-11-21 Burnham Institute, The Antiangiogenic endostatin peptides, endostatin variants and methods of use
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6685914B1 (en) * 1999-09-13 2004-02-03 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
BR0014222A (pt) * 1999-09-23 2003-02-25 Scripps Research Inst Método e composições para inibir a formação de adesão
US20080038274A1 (en) * 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
JP2003510371A (ja) * 1999-10-04 2003-03-18 カイロン コーポレイション 乾癬を処置するためのｃｄ４０アンタゴニスト
AU781444B2 (en) 1999-12-22 2005-05-26 Scripps Research Institute, The Angiogenesis and vascular permeability modulators and inhibitors
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
HUP0300544A3 (en) 2000-02-03 2005-03-29 Eisai Co Ltd Pharmaceutical compositions containing integrin expression inhibitors
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
US20010053766A1 (en) * 2000-02-11 2001-12-20 Janardan Kumar Method of treating disorders of the eye
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6835806B2 (en) 2000-04-03 2004-12-28 Phoenix Pharmaceuticals, Inc. Cell growth regulation system
ES2244607T3 (es) 2000-04-12 2005-12-16 Amersham Health As Derivados peptidicos de union a integrina.
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20030104573A1 (en) * 2000-09-11 2003-06-05 Shimkets Richard A. Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
JP2005508831A (ja) * 2000-10-02 2005-04-07 ザ スクリプス リサーチ インスティテュート 血管新生促進のための方法および組成物
US6632835B2 (en) 2001-02-22 2003-10-14 Nanodesign Inc. Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
DE10109136A1 (de) * 2001-02-26 2002-09-12 Cytotools Gmbh Mittel, die die Apoptose bei an der Wundheilung beteiligten Zellen inhibieren
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
AU2002316855B2 (en) 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
SE0101854L (sv) * 2001-05-28 2002-11-29 Bioneris Ab Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
AU2002312566A1 (en) * 2001-07-09 2003-01-29 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
HU230901B1 (hu) 2001-07-10 2019-01-28 Ge Healthcare Limited Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
MXPA04000204A (es) * 2001-07-27 2004-03-18 Univ Kansas Medical Center Estructura cristalizada de colageno tipo iv del hexamero de dominio nc1.
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US20030119834A1 (en) * 2001-09-05 2003-06-26 Bamdad Cynthia C. Compositions and methods of treatment of cancer
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
CN1658894A (zh) * 2002-02-14 2005-08-24 默克专利股份有限公司 用于治疗眼病的方法和组合物
JP2005522451A (ja) * 2002-02-15 2005-07-28 リヒャルト ブルンネル 脈絡膜の新生血管形成の治療のための７ｓ免疫グロブリン
WO2003075741A2 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
US20040001835A1 (en) * 2002-03-04 2004-01-01 Medimmune, Inc. Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
AU2003226065B2 (en) * 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
NZ584715A (en) 2002-07-15 2011-12-22 Univ Texas Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer
GB0217018D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 1
JP2005538093A (ja) * 2002-07-23 2005-12-15 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
WO2004058044A2 (en) * 2002-11-19 2004-07-15 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US20040176272A1 (en) * 2003-01-30 2004-09-09 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
AU2004209457A1 (en) 2003-02-06 2004-08-19 Tripep Ab Antigen/antibody or ligand/receptor glycosylated specificity exchangers
US7335359B2 (en) * 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
WO2004091510A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
JP2007523839A (ja) * 2003-04-18 2007-08-23 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 血管新生性障害の治療法
JP2007525187A (ja) * 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
BRPI0410875A (pt) * 2003-05-30 2006-07-04 Centocor Inc método de inibição do crescimento de tumor com anticorpos de fator antitecido
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US20050170455A1 (en) * 2003-06-20 2005-08-04 Qun-Yong Zhou Novel prokineticin receptor isoforms and methods of use
WO2005053683A1 (en) * 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
ES2410587T3 (es) 2004-01-22 2013-07-02 University Of Miami Formulaciones tópicas de coenzima Q10 y métodos de uso
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
US20050271650A1 (en) * 2004-02-17 2005-12-08 Cellmatrix, Inc. Method and composition for angiogenesis inhibition
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
WO2005117936A2 (en) * 2004-05-07 2005-12-15 The University Of North Carolina At Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-i
AU2005245896A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
EP1765362B1 (en) 2004-06-04 2012-03-28 The Scripps Research Institute Compositions and methods for treatment of neovascular diseases
EP1771565B1 (en) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
US20060029544A1 (en) * 2004-08-06 2006-02-09 The Regents Of The University Of California Office Of Technology Transfer Receptor-binding cyclic peptides and methods of use
US7659374B2 (en) * 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
KR100679100B1 (ko) * 2004-10-29 2007-02-06 엘지.필립스 엘시디 주식회사 수평 전계 인가형 액정 표시 패널 및 그 제조방법
EP2364995A1 (en) * 2004-12-23 2011-09-14 Molmed SpA Conjugation product
US20080317752A1 (en) * 2005-04-18 2008-12-25 Sloan-Kettering Institute For Cancer Research Inhibition of Tumorigenesis by Inhibition of a6b4 Integrin
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
US20060286148A1 (en) * 2005-05-18 2006-12-21 Ppd, Inc. Method of forming implants
WO2006138429A2 (en) 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
WO2007024921A2 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
ES2425396T3 (es) 2006-01-18 2013-10-15 Merck Patent Gmbh Terapia específica usando ligandos de integrinas para el tratamiento del cáncer
US20090220463A1 (en) 2006-01-19 2009-09-03 Doo-Sik Kim Pharmaceutical Composition For Treating Vascular-Related Diseases Comprising Peptide
AU2007257683A1 (en) * 2006-06-12 2007-12-21 Symphogen A/S Pan-cell surface receptor- specific therapeutics
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
AU2007284690A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
DK2101805T3 (da) 2007-01-18 2013-01-21 Merck Patent Gmbh Integrinligander til anvendelse i behandling af cancer
DK2025685T3 (da) * 2007-08-15 2013-09-02 Canadian Blood Services Monoklonale antistoffer mod BETA3-integriner.
EP2205629A2 (en) * 2007-10-16 2010-07-14 Symphogen A/S Compositions comprising optimized her1 and her3 multimers and methods of use thereof
KR20100102110A (ko) 2007-11-09 2010-09-20 페레그린 파마수티컬즈, 인크 항-ｖｅｇｆ 항체 조성물 및 방법
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
CA2737146A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
EP2352817B1 (en) 2008-10-31 2016-01-27 University Of Louisville Research Foundation, Inc. Olfactory epithelial-derived stem cells and methods of use therefor
EP2374002A1 (en) 2008-12-23 2011-10-12 GE Healthcare UK Limited Application of 99mtc peptide-based compound as a bone marrow imaging agent
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
JP2012528079A (ja) 2009-05-25 2012-11-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためのインテグリンリガンドの連続投与
FR2949782B1 (fr) * 2009-09-04 2015-10-16 Isp Investments Inc Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
CN103153328A (zh) 2010-07-16 2013-06-12 默克专利股份有限公司 肽在乳腺癌和/或骨转移灶的治疗中的用途
PL2672994T3 (pl) 2011-02-11 2018-11-30 Merck Patent Gmbh Przeciwciało przeciwko integrynie alfa-v do leczenia raka prostaty
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
RU2531502C2 (ru) * 2011-08-09 2014-10-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ повышения ангиогенной активности стромальных клеток жировой ткани
RU2481115C1 (ru) * 2011-10-13 2013-05-10 Общество с ограниченной ответственностью Научно-Производственное Объединение "Тюменькриобанк" Средство для заживления ран "целльгель", способ его получения и способ лечения ран различной этиологии полученным средством
US9775803B2 (en) 2011-10-19 2017-10-03 Samsung Electronics Co., Ltd. Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
TWI580692B (zh) * 2012-06-07 2017-05-01 國立成功大學 經修飾纖維黏連蛋白片段或變體及其用途
WO2014036385A1 (en) 2012-08-31 2014-03-06 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1)
WO2014063012A1 (en) 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
WO2014087429A1 (en) 2012-12-07 2014-06-12 Council Of Scientific & Industrial Research Histidinylated cationic amphiphiles, process for preparation thereof and their liposomal formulation
US9921224B2 (en) * 2013-03-14 2018-03-20 Children's Medical Center Corporation Use of CD36 to identify cancer subjects for treatment
JP7034914B2 (ja) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
US10786471B2 (en) 2017-02-06 2020-09-29 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
KR102630070B1 (ko) 2017-03-31 2024-01-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 알파-v 베타-3-양성인 암 줄기 세포(csc)를 표적화하여 사멸시키고 약물 내성 암을 치료하기 위한 조성물 및 방법
KR102171433B1 (ko) * 2018-05-25 2020-11-02 고려대학교 산학협력단 조직 재생을 위한 Substance P 펩타이드가 고정된 피브린 젤 및 이의 제조방법
EP3916014A4 (en) * 2019-07-24 2022-10-26 Korea Basic Science Institute SINGLE DOMAIN ANTIBODIES TARGETED AGAINST AVSS3 INTEGRIN
AU2020324391A1 (en) * 2019-08-02 2022-01-20 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (CSCS) and treating drug resistant and metastatic cancers
KR20230078657A (ko) 2020-08-27 2023-06-02 에노시 테라퓨틱스 코퍼레이션 자가면역 질환 및 암을 치료하기 위한 방법 및 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
JPH02502156A (ja) * 1987-11-19 1990-07-19 スクリップス　クリニック　アンド　リサーチ　ファウンデーション 内皮細胞のｒｇｄ指向粘着レセプターに対するモノクローナル抗体
JPH01169343A (ja) 1987-12-25 1989-07-04 Nippon Sheet Glass Co Ltd ガラス板の切口欠点検出装置
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
DE68910113T2 (de) * 1988-01-19 1994-03-17 Childrens Hospital Corp Wachstuminhibierendes mittel und dessen verwendung.
US5575815A (en) 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5686566A (en) 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5262520A (en) * 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
EP0470569B1 (en) * 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis inhibiting substance
CA2048078A1 (en) * 1990-11-15 1992-05-16 Wolfgang A. Wrasidlo Chemical modification of antibodies for creation of immunoconjugates
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
JP3353209B2 (ja) 1992-04-03 2002-12-03 ジェネンテク，インコーポレイテッド αｖβ３インテグリンに対する抗体
SK57693A3 (en) * 1992-06-18 1994-07-06 Merck Patent Gmbh Linear peptides and pharmaceutical agents on their base
UA43823C2 (uk) 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
ATE250138T1 (de) 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper
WO1994018221A1 (en) * 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing polypeptide binding sites
DE4310643A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
WO1995012412A1 (en) † 1993-11-05 1995-05-11 Centocor, Inc. Platelet-specific chimeric immunoglobulin and methods of use therefor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19538741A1 (de) 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate

Also Published As

Publication number Publication date
NZ283022A (en) 2001-05-25
CA2184493A1 (en) 1995-09-28
RU2162712C2 (ru) 2001-02-10
SK284586B6 (sk) 2005-07-01
EP1410807B1 (en) 2010-12-08
FI963692A0 (fi) 1996-09-18
EP0754059A1 (en) 1997-01-22
MX9604145A (es) 1998-05-31
CA2184493C (en) 2010-05-11
EP1468695A1 (en) 2004-10-20
HK1013960A1 (en) 1999-09-17
KR100327081B1 (ko) 2002-10-18
FI963692A (fi) 1996-09-18
EP0754059A4 (en) 1997-07-30
FI121916B (fi) 2011-06-15
NZ511293A (en) 2005-06-24
US7482007B2 (en) 2009-01-27
HU221988B1 (hu) 2003-03-28
EP0754059B1 (en) 2003-12-10
NZ548433A (en) 2008-04-30
KR970701564A (ko) 1997-04-12
CN1151120A (zh) 1997-06-04
SI0754059T2 (sl) 2011-12-30
DE69532279T3 (de) 2011-11-17
ATE534403T1 (de) 2011-12-15
DK1410807T3 (da) 2011-03-07
CN1161152C (zh) 2004-08-11
CZ271196A3 (cs) 1998-01-14
ATE255907T1 (de) 2003-12-15
SK119096A3 (en) 1997-07-09
NO963894L (no) 1996-11-18
US20040265317A1 (en) 2004-12-30
EP0754059B2 (en) 2011-08-24
JPH10500398A (ja) 1998-01-13
NO322441B1 (no) 2006-10-09
US5766591A (en) 1998-06-16
JP2006273862A (ja) 2006-10-12
US20050002936A1 (en) 2005-01-06
AU709645B2 (en) 1999-09-02
SI0754059T1 (en) 2004-06-30
DE69532279D1 (de) 2004-01-22
ES2211901T5 (es) 2011-12-12
DK0754059T3 (da) 2004-04-13
JP4268222B2 (ja) 2009-05-27
AU1995295A (en) 1995-10-09
US7595051B2 (en) 2009-09-29
ES2355074T3 (es) 2011-03-22
NO963894D0 (no) 1996-09-17
HUT76086A (en) 1997-06-30
ES2376850T3 (es) 2012-03-20
HU9602541D0 (en) 1996-11-28
ES2211901T3 (es) 2004-07-16
CZ294650B6 (cs) 2005-02-16
US20080175840A1 (en) 2008-07-24
UA44729C2 (uk) 2002-03-15
DK0754059T4 (da) 2011-09-19
JP4758281B2 (ja) 2011-08-24
PT1468695E (pt) 2012-02-09
US6887473B1 (en) 2005-05-03
US7354586B2 (en) 2008-04-08
EP1410807A1 (en) 2004-04-21
US7329406B2 (en) 2008-02-12
WO1995025543A1 (en) 1995-09-28
DE69532279T2 (de) 2004-09-16
EP1468695B1 (en) 2011-11-23
PT754059E (pt) 2004-04-30
DE69536128D1 (de) 2011-01-20
ATE490784T1 (de) 2010-12-15
US20040258691A1 (en) 2004-12-23
DK1468695T3 (da) 2012-02-27
US5753230A (en) 1998-05-19

Similar Documents

Publication Publication Date Title
ZA952214B (en) Methods and compositions useful for inhibiting angiogenesis
AR243728A1 (es) Metodo para producir una composicion humectante de tejidos epiteliales.
HUP9902099A3 (en) Methods and compositions useful for inhibition of angiogenesis
HU9403655D0 (en) Methods of inhibiting atrophy of the skin and vagina
HU9202420D0 (en) An activating agent for biosynthesis of gen macrolids
PL295838A1 (en) Method of renovating railroad tracks and set of machinery therefor
IL117988A0 (en) A new combination of an inhibitor and an antagonist
NZ245448A (en) Composition and method for the amelioration of organ tissue injury comprising monophosphoryl lipid a and carrier
HU9600241D0 (en) Mutable composition and methods of use thereof
GR3032317T3 (en) Synergistic herbicidal composition and method of use thereof
AU7997491A (en) Extended-release plaque preventing and dissolving compositions and their method of use
AU4596896A (en) Substituted benzamides and radioligand analogs and methods of use
HUT74963A (en) Methods for inhibiting of white blush of processed carrots
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
IL103752A0 (en) Method of normalizing soft tissue dysfunction
GB9410844D0 (en) Preparation of copolymers of carbon monoxide and an alpha-olefin having more than 10 carbon atoms
GB9308478D0 (en) Methods and compositions for amelioration of skin wrinkles
TW343909B (en) Fungicidal mixtures
PL270377A1 (en) Method of obtaining an emulsifying composition
TW310849U (en) Structure of hidden microphone for goggle
GB2293262B (en) Method and integrated circuit for the flexible combination of four operators in sound synthesis
NZ335183A (en) The 3-sulphate salt of 17-(alpha,delta) and 17-(beta,delta)-8(9)-dehydroestradiol and use as antioxidants
GB9411032D0 (en) Synthesis of substituted diaminophthalimides and analogues
GB9407673D0 (en) Peptide inhibitors of mitogenesis and motogenius
PL292946A1 (en) Top of an operating and diagnostic table